Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 11/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL3064256 | 0.95 | STAT3 (0.51) | STAT3ABCB1OPRM1OPRD1OPRK1 | |
| SCHEMBL3057622 | 0.90 | STAT3 (0.53) | STAT3PIK3CAPRKAA2PTGS2DRD2 | |
| SCHEMBL3065449 | 0.90 | STAT3 (0.53) | STAT3PIK3CAPRKAA2PTGS2DRD2 | |
| Bromide SCHEMBL3063277 | 0.89 | STAT3 (0.53) | STAT3PIK3CAPRKAA2PTGS2DRD2 | |
| Bromide SCHEMBL3067852 | 0.89 | STAT3 (0.53) | STAT3PIK3CAPRKAA2PTGS2DRD2 | |
| SCHEMBL3064421 | 0.87 | STAT3 (0.52) | STAT3PIK3CAPRKAA2PTGS2DRD2 | |
| SCHEMBL3060710 | 0.86 | STAT3 (0.51) | STAT3PIK3CAPRKAA2PTGS2DRD2 | |
| SCHEMBL10182182 | 0.84 | PTGS2 (0.51) | STAT3PIK3CAPRKAA2PTGS2DRD2 | |
| Bromide SCHEMBL3051765 | 0.83 | STAT3 (0.49) | STAT3PIK3CAPRKAA2PTGS2 | |
| SCHEMBL10180601 | 0.83 | STAT3 (0.62) | STAT3PIK3CAPRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | STAT3 1499/4885ABCB1 900/4885OPRM1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.